Language: BG BG
← Back to results
Recruiting Phase 2/3 NCT07548632

A Clinical Study Evaluating Licaminlimab for Dry Eye Disease

Phase 2/3 – combined trial
Conditions: Dry Eye Disease (DED)

Sponsor: Oculis

trial.available_in: БГ
Overview
The primary objective of this study is to evaluate the efficacy and safety of the topical ophthalmic administration of licaminlimab as compared to vehicle in participants with Dry Eye Disease and a specific genotype.
Who can participate
Key Inclusion Criteria: * Physician diagnosis of Dry Eye Disease in the past 6 months * Use of over-the-counter tears * Must agree to genotype testing Key Exclusion Criteria: \- Have a history or presence of any disorder or condition that may, in the opinion of the Investigator, likely interfere with the interpretation of the study results or participant safety.
Interventions
Artificial Tear Run-in
OTHER
licaminlimab
DRUG
Vehicle of licaminlimab
OTHER
Locations 10
United States (10)
Vision Institute
Colorado Springs , Colorado
NOT_YET_RECRUITING
Scott & Christie and Associates
Cranberry Township , Pennsylvania
Segal Drug Trials, Inc.
Delray Beach , Florida
NOT_YET_RECRUITING
Erie Retina Research
Erie , Pennsylvania
NOT_YET_RECRUITING
Oculus Research, Inc.
Garner , North Carolina
Global Research Management
Glendale , California
NOT_YET_RECRUITING
Piedmont Eye Center, Inc.
Lynchburg , Virginia
NOT_YET_RECRUITING
Total Eye Care, PA
Memphis , Tennessee
Eye Research Foundation
Newport Beach , California
CORE, Inc
Shelby , North Carolina
NOT_YET_RECRUITING
Technical details
Status
Recruiting
Phase
Phase 2/3
Study type
INTERVENTIONAL
Sex
Male and female
Minimum age
18 Years
Healthy volunteers
No
Start date
16.04.2026
Completion date
01.12.2026
Registry ID
NCT07548632
Source
clinicaltrials.gov
trial.inquiry_btn

Information is automatically extracted from ClinicalTrials.gov. Consult your doctor before taking action.